The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Open accessAbstract
Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been identified in gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel enzymatic property of producing 2-hydroxyglutarate (2HG) from α-ketoglutarate. Here we report that 2HG-producing IDH mutants can prevent the histone demethylation that is required for lineage-specific progenitor cells to differentiate into terminally differentiated cells. In tumour samples from glioma patients, IDH mutations were associated with a distinct gene expression profile enriched for genes expressed in neural progenitor cells, and this was associated with increased histone methylation. To test whether the ability of IDH mutants to promote histone methylation contributes to a block in cell differentiation in non-transformed cells, we tested the effect of neomorphic IDH mutants on adipocyte differentiation in vitro. Introduction of either mutant IDH or cell-permeable 2HG was associated with repression of the inducible expression of lineage-specific differentiation genes and a block to differentiation. This correlated with a significant increase in repressive histone methylation marks without observable changes in promoter DNA methylation. Gliomas were found to have elevated levels of similar histone repressive marks. Stable transfection of a 2HG-producing mutant IDH into immortalized astrocytes resulted in progressive accumulation of histone methylation. Of the marks examined, increased H3K9 methylation reproducibly preceded a rise in DNA methylation as cells were passaged in culture. Furthermore, we found that the 2HG-inhibitable H3K9 demethylase KDM4C was induced during adipocyte differentiation, and that RNA-interference suppression of KDM4C was sufficient to block differentiation. Together these data demonstrate that 2HG can inhibit histone demethylation and that inhibition of histone demethylation can be sufficient to block the differentiation of non-transformed cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
In the citing paper
“In addition to its epigenetic effects, D-2HG inhibits enzymes from the canonical metabolic network (104). Such enzymes include transaminases that produce glutamate for glutathione biosynthesis, rendering IDH-mutant gliomas susceptible to treatments that deplete glutamate and enhance oxidative stress (105).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [104]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [118]
In the citing paper
“a neomorphic mutation in IDH1 and/or IDH2 causes a change in enzymatic activity and the accumulation of 2-hydroxyglutarate (2-HG), which inhibits the function of αKG-dependent enzymes such as TET2, resulting in the loss of 5hmC, an increase in DNA methylation and ultimately altered gene expression programmes that drive cancer development66.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [66]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [173]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
Self-citationFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citationIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
Self-citation
Cited by
Sorted by citations
Items 701–800 of 1,001
Targeting metabolic pathways for head and neck cancers therapeutics
Yamamoto, M., Inohara, H., & Nakagawa, T. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9691-z · Cited by 44
Linninger, A. A., Hartung, G. A., Liu, B. P., Mirkov, S., Tangen, K. M., Lukas, R. V., Unruh, D. J., James, C. D., Sarkaria, J. N., & Horbinski, C. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy051 · Cited by 47
Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer
Dahl, E. S., Buj, R., Leon, K. E., Newell, J. M., Kawasawa, Y. I., Bitler, B. G., Snyder, N. W., & Aird, K. M. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1233 · Cited by 44
Janke, R., Iavarone, A. T., & Rine, J. (2017) · eLife · doi:10.7554/elife.22451 · Cited by 40
Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions
Gilbert, A., Tudor, M., Montanari, J., Commenchail, K., Savu, D., Lesueur, P., & Chevalier, F. (2023) · Cancers · doi:10.3390/cancers15071962 · Cited by 51
Alberghina, L., Gaglio, D., Gelfi, C., Moresco, R. M., Mauri, G., Bertolazzi, P., Messa, C., Gilardi, M. C., Chiaradonna, F., & Vanoni, M. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00362 · Cited by 45
Hwang, V. J., Kim, J., Rand, A. A., Yang, C., Sturdivant, S., Hammock, B. D., Bell, P. D., Guay‐Woodford, L. M., & Weiss, R. H. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00238.2015 · Cited by 43
Pathogenesis of Myeloproliferative Disorders
Nangalia, J., Grinfeld, J., & Green, A. R. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044454 · Cited by 48
Abedalthagafi, M., Wu, M. P., Merrill, P. H., Du, Z., Woo, T. Y. C., Sheu, S., Hurwitz, S., Ligon, K. L., & Santagata, S. (2015) · The Journal of Pathology · doi:10.1002/path.4682 · Cited by 43
Characteristics of gliomas in patients with somatic IDH mosaicism
Bonnet, C., Thomas, L., Psimaras, D., Bielle, F., Vauléon, É., Loiseau, H., Cartalat‐Carel, S., Meyronet, D., Dehais, C., Honnorat, J., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0302-y · Cited by 43
Joberty, G., Böesche, M., Brown, J. A., Eberhard, D., Garton, N. S., Humphreys, P. G., Mathieson, T., Muelbaier, M., Ramsden, N. G., Reader, V., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00080 · Cited by 44
Analyzing Tumor Metabolism In Vivo
Faubert, B., & DeBerardinis, R. J. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121954 · Cited by 44
Studies on the regulatory mechanism of isocitrate dehydrogenase 2 using acetylation mimics
Xu, Y., Liu, L., Nakamura, A., Someya, S., Miyakawa, T., & Tanokura, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10337-7 · Cited by 47
Metabolic Signaling to Epigenetic Alterations in Cancer
Kim, J., & Yeom, Y. I. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.185 · Cited by 45
Metabolism and Transcription in Cancer: Merging Two Classic Tales
Martín-Martín, N., Carracedo, A., & Torrano, V. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00119 · Cited by 43
Zhou, Z., Ibekwe, E., & Chornenkyy, Y. (2018) · Antioxidants · doi:10.3390/antiox7010016 · Cited by 44
Enasidenib for the treatment of acute myeloid leukemia
Dugan, J. P., & Pollyea, D. A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1477585 · Cited by 43
Abe, H., Natsumeda, M., Kanemaru, Y., Watanabe, J., Tsukamoto, Y., Okada, M., Yoshimura, J., Oishi, M., & Fujii, Y. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0044 · Cited by 43
Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors
Werner, J., Lohmann, P., Fink, G. R., Langen, K., & Galldiks, N. (2020) · Molecules · doi:10.3390/molecules25061471 · Cited by 43
Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas
Wu, J., Castro, L. N. G., Battaglia, S., Farran, C. A. E., D’Antonio, J. P., Miller, T. E., Suvà, M. L., & Bernstein, B. (2024) · Nature Cancer · doi:10.1038/s43018-024-00865-3 · Cited by 48
IDH mutations in liver cell plasticity and biliary cancer
Saha, S. K., Parachoniak, C. A., & Bardeesy, N. M. (2014) · Cell Cycle · doi:10.4161/15384101.2014.965054 · Cited by 46
The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture
Salomoni, P. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00152 · Cited by 46
Cagnetta, A., Adamia, S., Acharya, C., Patrone, F., Miglino, M., Nencioni, A., Gobbi, M., & Cea, M. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.006 · Cited by 42
Macrophage activation as an archetype of mitochondrial repurposing
Jones, A. E., & Divakaruni, A. S. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.100838 · Cited by 41
Jaramillo, S., & Schlenk, R. F. (2023) · Haematologica · doi:10.3324/haematol.2022.280802 · Cited by 44
Sepsa, A., Levidou, G., Gargalionis, A. N., Adamopoulos, C., Spyropoulou, A., Dalagiorgou, G., Thymara, I., Boviatsis, E. I., Themistocleous, M. S., Petraki, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115101 · Cited by 41
Cancer metabolism as a central driving force of glioma pathogenesis
Masui, K., Cavenee, W. K., & Mischel, P. S. (2016) · Brain Tumor Pathology · doi:10.1007/s10014-016-0265-5 · Cited by 40
Lee, J. C., Solomon, D. A., & Tihan, T. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2349-9 · Cited by 45
Bailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41
Metabolic underpinnings of leukemia pathology and treatment
Nemkov, T. G., D’Alessandro, A., & Reisz, J. A. (2018) · Cancer Reports · doi:10.1002/cnr2.1139 · Cited by 46
Prabhu, A. H., Kant, S., Kesarwani, P., Ahmed, K. A., Forsyth, P. A., Nakano, I., & Chinnaiyan, P. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy185 · Cited by 38
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment
Gatto, L., Franceschi, E., Tosoni, A., Nunno, V. D., Maggio, I., Lodi, R., & Brandes, A. A. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00537-3 · Cited by 44
Armstrong, N., Storey, C. M., Noll, S. E., Margulis, K., Soe, M. H., Xu, H., Yeh, B. T., Fishbein, L. M., Kebebew, E., Howitt, B. E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110453 · Cited by 42
Cancer anabolic metabolism inhibitors move into clinic
Garber, K. (2016) · Nature Biotechnology · doi:10.1038/nbt0816-794 · Cited by 41
Sarkaria, S. M., Christopher, M. J., Klco, J. M., & Ley, T. J. (2014) · Leukemia · doi:10.1038/leu.2014.235 · Cited by 40
Extensive Decoupling of Metabolic Genes in Cancer
Reznik, E., & Sander, C. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004176 · Cited by 39
Molecular Pathways: IDH2 Mutations—Co-opting Cellular Metabolism for Malignant Transformation
Stein, E. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0362 · Cited by 40
Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells
Smolková, K., Dvořák, A., Zelenka, J., Vı́tek, L., & Ježek, P. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.05.012 · Cited by 39
Chen, Y., Widschwendter, M., & Teschendorff, A. E. (2017) · Genome biology · doi:10.1186/s13059-017-1366-0 · Cited by 40
Liu, W., Chan, S., Chang, H., Li, G., Tu, Y.-T., Tseng, H., Fu, T., Chang, H.-Y., Liou, H., Ger, L., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0953-7 · Cited by 40
Grade II and III Oligodendroglioma and Astrocytoma
van den Bent, M. J., & Chang, S. M. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.04.005 · Cited by 44
Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics
Vega, J. E. V., & Brat, D. J. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000186 · Cited by 40
Gulaia, V. S., Kumeiko, V. V., Shved, N. A., Cicinskas, E., Александрович, Р. С., Ruzov, A. S., & Kagansky, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00388 · Cited by 39
Molecular Pathogenesis of Low-Grade Glioma
Bready, D., & Placantonakis, D. G. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.08.011 · Cited by 40
2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation
Schvartzman, J. M., Reuter, V. P., Koche, R. P., & Thompson, C. B. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817662116 · Cited by 43
Self-citationMitochondrial aconitase controls adipogenesis through mediation of cellular ATP production
Chen, Y., Cai, G. H., Xia, B., Wang, X., Zhang, C. C., Xie, B., Shi, X., Liu, H., Lu, J. F., Zhang, R. X., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201903224rr · Cited by 39
How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications
Acker, H. H. V., Ma, S., Scolaro, T., Kaech, S. M., & Mazzone, M. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.03.006 · Cited by 39
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 42
The contribution of mitochondrial DNA alterations to aging, cancer, and neurodegeneration
Picca, A., Guerra, F., Calvani, R., Coelho‐Júnior, H. J., Leeuwenburgh, C., Bucci, C., & Marzetti, E. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112203 · Cited by 43
Verma, A., & Lindroth, A. M. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01537-7 · Cited by 47
Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors
Fontebasso, A. M., Gayden, T., Nikbakht, H., Neirinck, M., Papillon‐Cavanagh, S., Majewski, J., & Jabado, N. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1325-8 · Cited by 40
Poinsignon, V., Mercier, L., Nakabayashi, K., David, M. D., Lalli, A., Penard‐Lacronique, V., Quivoron, C., Saada, V., de Botton, S., Broutin, S., et al. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.04.030 · Cited by 43
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia
Ragon, B. K., & Dinardo, C. D. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0418-6 · Cited by 39
Molecular markers and targeted therapy in pediatric low-grade glioma
de Blank, P. M. K., Fouladi, M., & Huse, J. T. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03529-1 · Cited by 41
Clinical and Therapeutic Implications of Cancer Stem Cells
Shin, S. W. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1908886 · Cited by 39
Metabolic Plasticity and Epithelial-Mesenchymal Transition
Thomson, T. M., Balcells, C. D., & Cascante, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070967 · Cited by 39
Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
Trejo‐Solís, C., Castillo‐Rodríguez, R. A., Serrano-García, N., Silva‐Adaya, D., Vargas-Cruz, S., Chávez-Cortéz, E. G., Gallardo‐Pérez, J. C., Zavala-Vega, S., Cruz-Salgado, A., & Magaña-Maldonado, R. (2024) · Metabolites · doi:10.3390/metabo14050249 · Cited by 41
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer
Jiang, H., & Ye, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.03.006 · Cited by 40
IDH1, lipid metabolism and cancer: Shedding new light on old ideas
Bogdanovic, E. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.04.014 · Cited by 39
Benoit, Y. D., Guezguez, B., Boyd, A. L., & Bhatia, M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2491 · Cited by 40
Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
Ohba, S., & Hirose, Y. (2016) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2015-0322 · Cited by 38
Doll, S., Urisman, A., Osés-Prieto, J. A., Arnott, D. P., & Burlingame, A. L. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.063883 · Cited by 39
Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia
Takao, S., Chien, W., Madan, V., Lin, D.-C., Ding, L.-W., Sun, Q.-Y., Mayakonda, A., Sudo, M., Xu, L., Chen, Y., et al. (2017) · Leukemia · doi:10.1038/leu.2017.281 · Cited by 38
Pisapia, D. J. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0493-ra · Cited by 43
Molecular and Genetic Determinants of Glioma Cell Invasion
Masui, K., Kato, Y., Sawada, T., Mischel, P. S., & Shibata, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122609 · Cited by 38
Hwang, I., Cao, D., Na, Y., Kim, D.-Y., Zhang, T., Yao, J., Oh, H., HU, J. L., Zheng, H., Yao, Y., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.02.013 · Cited by 38
Chaturvedi, A., Gupta, C., Gabdoulline, R. R., Borchert, N. M., Goparaju, R., Kaulfuß, S., Görlich, K., Schottmann, R., Othman, B., Welzenbach, J., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.236992 · Cited by 39
IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting
Salati, M., Caputo, F., Baldessari, C., Galassi, B., Grossi, F., Dominici, M., & Ghidini, M. (2020) · Cancers · doi:10.3390/cancers12113310 · Cited by 42
Magnetic resonance spectroscopy for the study of cns malignancies
Ruiz‐Rodado, V., Brender, J., Cherukuri, M. K., Gilbert, M. R., & Larion, M. (2020) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2020.11.001 · Cited by 37
Molecular targeted therapy: A new avenue in glioblastoma treatment (Review)
Atat, O. E., Naser, R., Abdelkhalek, M., Abi‐Habib, R. J., & El‐Sibai, M. (2022) · Oncology Letters · doi:10.3892/ol.2022.13632 · Cited by 40
The mechanisms of IDH mutations in tumorigenesis
Ye, D., Xiong, Y., & Guan, K. (2012) · Cell Research · doi:10.1038/cr.2012.51 · Cited by 38
Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells
Viswanath, P., Chaumeil, M. M., & Ronen, S. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00060 · Cited by 38
Current understanding of the human microbiome in glioma
Liang, J., Li, T., Zhao, J., Wang, C., & Sun, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.781741 · Cited by 37
Oizel, K., Gratas, C., Nadaradjane, A., Oliver, L., Vallette, F. M., & Pecqueur, C. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.13 · Cited by 38
Jafari‐Khouzani, K., Loebel, F., Bogner, W., Rapalino, O., González, R. G., Gerstner, E. R., Chi, A. S., Batchelor, T. T., Rosen, B. R., Unkelbach, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now100 · Cited by 37
IGFBP2 expression predicts IDH-mutant glioma patient survival
Huang, L. E., Cohen, A. L., Colman, H., Jensen, R. L., Fults, D. W., & Couldwell, W. T. (2016) · Oncotarget · doi:10.18632/oncotarget.13329 · Cited by 37
Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas
Filipski, K., Braun, Y., Zinke, J., Roller, B., Baumgarten, P., Wagner, M., Senft, C., Zeiner, P. S., Ronellenfitsch, M. W., Steinbach, J. P., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02025-9 · Cited by 36
Targeting the Ubiquitin System in Glioblastoma
Scholz, N., Kurian, K. M., Siebzehnrübl, F. A., & Licchesi, J. D. F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574011 · Cited by 37
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
Sun, X., & Turcan, Ş. (2021) · Cells · doi:10.3390/cells10051225 · Cited by 38
Falini, B., Sportoletti, P., Brunetti, L., & Martelli, M. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13409 · Cited by 38
Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters
Viswanath, P., Najac, C., Izquierdo-García, J. L., Pankov, A., Hong, C., Eriksson, P., Costello, J., Pieper, R. O., & Ronen, S. M. (2016) · Oncotarget · doi:10.18632/oncotarget.9006 · Cited by 35
Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.
Medinger, M., Lengerke, C., & Passweg, J. R. (2016) · Europe PMC (PubMed Central) · Cited by 36
Novel therapeutic options in Acute Myeloid Leukemia
Medinger, M., Lengerke, C., & Passweg, J. R. (2016) · Leukemia Research Reports · doi:10.1016/j.lrr.2016.09.001 · Cited by 36
Hardwick, J. S., Lane, A. N., & Brown, T. (2018) · BioEssays · doi:10.1002/bies.201700199 · Cited by 40
Gerecke, C., Schumacher, F., Berndzen, A., Homann, T., & Kleuser, B. (2019) · Epigenetics · doi:10.1080/15592294.2019.1666652 · Cited by 36
Non-Conventional Treatments for Conventional Chondrosarcoma
Monga, V., Mani, H., Hirbe, A. C., & Milhem, M. M. (2020) · Cancers · doi:10.3390/cancers12071962 · Cited by 38
Transcriptional regulators and alterations that drive melanoma initiation and progression
Gupta, R., Janoštiak, R., & Wajapeyee, N. (2020) · Oncogene · doi:10.1038/s41388-020-01490-x · Cited by 36
A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms
Guijarro-Hernández, A., & Vizmanos, J. L. (2021) · Cancers · doi:10.3390/cancers13050984 · Cited by 37
Bill, M., Jentzsch, M., Bischof, L., Kohlschmidt, J., Grimm, J., Schmalbrock, L. K., Backhaus, D., Brauer, D., Goldmann, K., Franke, G., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005789 · Cited by 35
Ensign, S. P. F., Jenkins, R. B., Giannini, C., Sarkaria, J. N., Galanis, E., & Kizilbash, S. H. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac205 · Cited by 40
Schaefer, I., Hornick, J. L., & Bovée, J. V. M. G. (2018) · Laboratory Investigation · doi:10.1038/s41374-017-0003-6 · Cited by 36
Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
Buege, M. J., DiPippo, A. J., & Dinardo, C. D. (2018) · Cancers · doi:10.3390/cancers10060187 · Cited by 35
TCA cycle-derived oncometabolites in cancer and the immune microenvironment
Sarkar, S., Chang, C.-I., Jean, J., & Wu, M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01186-y · Cited by 39
Peroxisome biogenesis in mammalian cells: The impact of genes and environment
Farr, R. L., Lismont, C., Terlecky, S. R., & Fransen, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.08.011 · Cited by 37
Mutant IDH1 is required for IDH1 mutated tumor cell growth
Jin, G., Pirozzi, C. J., Chen, L. H., Lopez, G. Y., Duncan, C. G., Feng, J., Spasojević, I., Bigner, D. D., He, Y., & Yan, H. (2012) · Oncotarget · doi:10.18632/oncotarget.577 · Cited by 37
Acute Myeloid Leukemia: Past, Present, and Prospects for the Future
Short, N. J., & Ravandi, F. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.007 · Cited by 34
Filipp, F. V. (2017) · Briefings in Functional Genomics · doi:10.1093/bfgp/elx001 · Cited by 40
Emerging therapies for acute myeloid leukemia: translating biology into the clinic
Kavanagh, S., Murphy, T., Law, A., Yehudai, D., Ho, J., Chan, S., & Schimmer, A. D. (2017) · JCI Insight · doi:10.1172/jci.insight.95679 · Cited by 37
Innate immune training and metabolic reprogramming in primary monocytes of broiler and laying hens
Verwoolde, M. B., van den Biggelaar, R. H. G. A., Reilingh, G. D. V., Arts, J. A. J., van Baal, J., Lammers, A., & Jansen, C. A. (2020) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2020.103811 · Cited by 37
Maeda, S., Ohka, F., Okuno, Y., Aoki, K., Motomura, K., Takeuchi, K., Hironao, K., Yanagisawa, N., Sato, S., Yamaguchi, J., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0882-4 · Cited by 34
Metadata
- Authors
- Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., Wellen, K. E., O’Rourke, D. M., Berger, S. L., Chan, T. A., Levine, R. L., Mellinghoff, I. K., & Thompson, C. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Pennsylvania (US)
- Weill Cornell Medicine (US)
- Corresponding author
- Thompson, Craig B.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 474-478
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3478770
- OpenAlex
- W2154313451
- Cited by
- 1,985
- References
- 30
- Citations by year
- 2026: 81 · 2025: 93 · 2024: 106 · 2023: 125 · 2022: 122 · 2021: 180 · 2020: 170 · 2019: 153 · 2018: 146 · 2017: 163 · 2016: 151 · 2015: 123 · 2014: 138 · 2013: 136 · 2012: 91
- FWCI
- 74.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- National Cancer Institute (R01CA078831, R01CA105463, U54CA143798)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- 2-hydroxyglutarate, histone demethylation, histone methylation, glioma, oncometabolites, DNA hypermethylation, hypoxia-inducible factor, adipogenesis, neural progenitor cells
- MeSH terms
- Animals, Astrocytes, Cell Differentiation, Enzyme Induction, Gene Expression Regulation, Glioma, Glutarates, Histones, Humans, Isocitrate Dehydrogenase, Methylation, Mutation, Promoter Regions, Genetic, Adipocytes, Cell Lineage, DNA Methylation, 3T3-L1 Cells, Cell Line, Tumor, Mice, Jumonji Domain-Containing Histone Demethylases, HEK293 Cells, Neural Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
